Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue SUPPL. 1, 2012, Pages

  Home, Philip ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ALEGLITAZAR; ALOGLIPTIN; CALCIUM CHANNEL; CHLORPROPAMIDE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNINDEXED DRUG; VILDAGLIPTIN;

ARTICLE; BLADDER CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHANNEL GATING; DRUG SAFETY; ENZYME INHIBITION; FLUID RETENTION; GLUCONEOGENESIS; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INHIBITION KINETICS; INSULIN RELEASE; MEDICAL RESEARCH; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, ORAL; ALPHA-GLUCOSIDASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84861890031     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0007     Document Type: Article

References (63)

1. Lebovitz HE, Banerji MA: Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-43-S-50.
2. Hirsch IB, O'Brien KD: How to best manage glycemia and non-glycemia during the time of acute myocardial infarction. Diabetes Technol Ther 2012;14(Suppl 1):S-22-S-32.
3. Bennett WL, Odelola OA, Wilson LM, Bolen S, Selvaraj S, Robinson KA, Bass EB, Puhan MA: Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: A systematic review. Ann Intern Med 2012;156:27-36.
4. Migoya EM, Bergeron R, Miller JL, Snyder RNK, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G, Liu F, Pryor KA, Yao J, Zhu L, Holst JJ, Deacon C, Herman G, Thornberry N, Amatruda J, Williams-Herman D, Wagner JA, SinhaRoy R: Gipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-808.
5. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
6. Dunn CJ, Peters DH: Metformin. A review of its pharmacological properties and therapeutic use in non-insulindependent diabetes mellitus. Drugs 1995;49:721-749.
7. Laakso M: Hyperglycaemia as a risk factor for cardiovascular disease. In: Marshall SM, Home PD, Rizza RA, eds. The Diabetes Annual 12. Amsterdam: Elsevier, 1999:317-328.
8. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828.
9. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM: Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 2000;6:998-1003.
10. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865. Erratum in Lancet 1998;352: 1558.
11. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. Erratum in Lancet 1999;354:602.
13. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
14. GlaxoSmithKline. Advisory Committee Briefing Document Cardiovascular Safety of Rosiglitazone, FDA Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. King of Prussia, PA: GlaxoSmithKline, 2007. www.fda.gov/ohrms/dockets/ac/07/briefing/ 2007-4308b1-01-sponsor-backgrounder.pdf (last accessed 06 January 2012).
15. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV; Record Study Team: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.
16. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515.
17. Lamanna C, Monami M, Marchionni N, Mannucci E: Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13:221-228.
18. Asplund K, Wiholm BE, Lithner F: Glibenclamide-associated hypoglycaemia: A report on 57 cases. Diabetologia 1983;24: 412-417.
19. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90:9-12.
20. Bilinska M, Potocka J, Korzeniowska-Kubacka I, Piotrowicz R: 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas. Coron Artery Dis 2007;18:455-462.
21. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W: Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-446.
22. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM; Sitagliptin Study 024 Group: Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract 2010;64: 562-576.
23. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J 2011;32:1900-1908.
24. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl):789-830.
25. Leibel B: An analysis of the University Group Diabetes Study Program: Gata results and conclusions. Can Med Assoc J 1971;105:292-294.
26. Johnsen SP, Monster TB, Olsen ML, Thisted H, McLaughlin JK, Sorensen HT, Lervang HH, Rungby J: Risk and shortterm prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006;13:134-140.
27. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90:9-12.
28. Asplund K, Wiholm B-E, Lithner F: Glibenclamide-associated hypoglycaemia: A report on 57 cases. Diabetologia 1983;24: 412-417.
29. Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-473.
30. Holman RR, Cull CA, Turner RC: A randomized doubleblind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999;22:960-964. Erratum in Diabetes Care 1999;22:1922.
31. Ceriello A: Impaired glucose tolerance and cardiovascular disease: The possible role of post-prandial hyperglycemia. Am Heart J 2004;147:803-807.
32. Guideline Development Group, International Diabetes Federation: Guideline for Management of Postmeal Glucose. www.idf.org/guidelines/postmeal-glucose (accessed December 1, 2011).
33. Ceriello A, Davidson J, Hanefeld M, Leiter L, Monnier L, Owens D, Tajima N, Tuomilehto J: Postprandial hyperglycaemia and cardiovascular complications of diabetes: An update. Nutr Metab Cardiovasc Dis 2006;16:453-456.
34. Esposito K, Giugliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-219.
35. Rosenthal JH, Mauersberger H: Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002; 22:695-701.
36. Hanefeld M, Cagatay M, Petrowitschb T, Neuserb D, Petzinnab D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-Term studies. Eur Heart J 2004;25:10-16.
37. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359: 2072-2077.
38. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD; Record Study Group: Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the Record study). Cardiovasc Diabetol 2008;7:10.
39. Oleksiewicz MB, Southgate J, Iversen L, Egerod FL: Rat urinary bladder carcinogenesis by dual-acting PPARa + c agonists. PPAR Res 2008;2008:103167.
40. Smith U: Pioglitazone: Mechanism of action. Int J Clin Pract Suppl 2001;121(Suppl):13-18.
41. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28: 1547-1554.
42. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD; Rosiglitazone Study 108 investigators: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-952.
43. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P; Record Study Group: Rosiglitazone Record study: Glucose control outcomes at 18 months. Diabet Med 2007;24:626-634.
44. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-1105. Erratum in Lancet 2006;368:1770.
45. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM: Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Safe 2007;16: 711-725.
46. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM: Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. BMJ 2009;339:b2942.
47. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-418.
48. McEvoy B: Pioglitazone and rosiglitazone cardiovascular safety meta-analyses. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Endocrinologicand MetabolicDrugsAdvisoryCommittee/ucm218481.htm (accessed July 13, 2010).
49. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289.
50. Holman RR, Retnakaran R, Farmer A, Stevens R: The PROactive study. Lancet 2006;367:25-26.
51. SmithKline Beecham: Avandia: Summary of Product Characteristics. 2006. www.emea.eu.int (accessed June 19, 2007).
52. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
53. Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-581.
54. Laws I, Home PD, Stewart M: Avandia (rosiglitazone maleate): Record study. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Endocrinologicand MetabolicDrugsAdvisoryCommittee/ucmLaws218481.htm (accessed July 13, 2010).
55. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
56. Callaghan F: Rosiglitazone Cardiovascular Safety Metaanalysis. www.fda.gov/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugs AdvisoryCommittee/ucm218481.htm (accessed July 13, 2010).
57. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ: Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
58. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W: Assessing the cardio-cerebrovascular safety of vildagliptin: Meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-494.
59. Frederich R,Alexander JH, Fiedorek FT, DonovanM, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27.
60. White WB, Gorelick PB, Fleck P, Smith N, Wilson C, Pratley R: Cardiovascular events in patients receiving alogliptin: A pooled analysis of randomized clinical trials [abstract]. Diabetes Poster 391-PP, 2010 American Diabetes Association Meeting, Orlando, FL. http://professional.diabetes.org/ Abstracts-Display.aspx?TYP =1&CID= 79331 (accessed March 5, 2012).
61. Center for Drug Evaluation and Research. Application Number: 201280orig1s000: Summary Review. www.access data.fda.gov/drugsatfda-docs/nda/ 2011/201280Orig1s000 SumR.pdf (accessed January 6, 2012).
62. Lamanna C, Monaroi M, Bartoli N, Zannoni S, Mannucci E: Gipeptidyl peptidase-4 inhibitors and cardiovascular events: A protective effect? [abstract]. Diabetologia 2011;54(Suppl 1):S109.
63. Food and Drug Administration: FDA Briefing Document; NDA 202293; Dapagliflozin Tablets, 5 and 10 mg. Advisory Committee Meeting July 19. 2011. www.fda.gov (accessed July 19, 2011).